REDWOOD CITY, Calif. and PHILADELPHIA, April 20, 2015 /PRNewswire/ -- Guardant Health, the leader in cell-free tumor DNA testing, is presenting data today on its findings from more than 2,000 clinical samples analyzed using Guardant360 at the 2015 American Association for Cancer Research (AACR) Annual Meeting. The poster presentation details that 99.5 percent of the samples were successfully analyzed across a wide range of cancer types, including colon, breast, lung, melanoma, gastric, glioblastoma and pancreatic cancers. It also highlights the wide genomic landscape found in lung cancer with Guardant360 as the only biopsy-free blood test that can identify all NCCN guideline recommended tumor genomic markers.
Eliminating the costs, complications, and delays associated with repeat invasive tissue biopsies, Guardant360® nearly eliminates false positives while detecting tumor genomic alterations in up to 85 percent for most cancer types, thereby allowing for sequencing of long-targeted regions across many genes at very low concentrations. Specifically, the data highlights that 25 percent of circulating DNA alterations detected in the large sample set were identified at or below 0.2 percent frequencies. This reinforces the need for a sensitive assay that offers ultra-high fidelity despite the high error rate of standard next-generation DNA sequencing platforms. Also presented is data illustrating how Guardant360 quantitatively differentiates somatic (tumor) from germline (normal) alterations, a further advantage over tissue biopsy genomic profiling methods that can fail to distinguish between the two.
"Guardant360 now offers a comprehensive biopsy-free option that empowers oncologists and patients to gain greater visibility into cancers without the cost or pain associated with traditional methods," said AmirAli Talasaz, co-founder, President and COO of Guardant Health. "The clinical benefit seen by physicians and their patients is fueling strong market adoption of Guardant360."
With only two vials of blood, Guardant360® digitally sequences billions of genomic data points to identify tumor genomic alterations with single molecule sensitivity at specificity greater than 99.9999 percent. Actionable genomic alterations and associated treatments are identified with none of the risks and half of the turnaround time of tissue biopsies. The Guardant360 platform gives oncologists and patients a simpler, faster and more accurate perspective of their treatment options, resulting in targeted therapies for genomic alterations.
The clinical utility data will be presented as a poster, Monday, April 20 from 1 p.m. – 5 p.m. ET.
Title: Biopsy-Free Comprehensive tumor profiling of 2,000+ consecutive cancer patients using a CLIA-certified commercial test and its clinical utility
Location: Section 21
Poster Board Number: 6
Presenters: Eric Collisson, UCSF, San Francisco, CA
About Guardant Health
Guardant Health, headquartered in Redwood City, Calif., is focused on developing breakthrough diagnostics that can transform cancer from a silent killer into a manageable disease. Guardant Health was founded in 2012 by a team of serial entrepreneurs with expertise in next-generation sequencing, single-cell genomics and cancer diagnostics. The company has raised $100 million in funding from leading venture capital firms and its first product, Guardant360, came to market in 2014. The team is committed to positively and significantly impacting patient health through technology that addresses long-standing unmet needs in oncology.
Mark de la Vina
Consort Partners for Guardant Health
Email: [email protected]
SOURCE Guardant Health